argenx SE’s (NASDAQ:ARGX) lock-up period is set to expire on Tuesday, November 14th. argenx SE had issued 5,865,000 shares in its initial public offering on May 18th. The total size of the offering was $99,705,000 based on an initial share price of $17.00. After the end of argenx SE’s lock-up period, company insiders and major shareholders will be able to sell their shares of the company.
A number of research analysts recently issued reports on ARGX shares. Zacks Investment Research downgraded shares of argenx SE from a “buy” rating to a “hold” rating in a research note on Wednesday, October 25th. Cowen and Company reiterated a “buy” rating on shares of argenx SE in a research note on Thursday, August 24th.
ILLEGAL ACTIVITY WARNING: “argenx SE’s (ARGX) Lock-Up Period Set To Expire Tomorrow” was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://ledgergazette.com/2017/11/13/argenx-ses-argx-lock-up-period-set-to-expire-tomorrow.html.
argenx SE (ARGX) opened at $24.15 on Monday. argenx SE has a 12 month low of $17.33 and a 12 month high of $27.25.
Hedge funds have recently added to or reduced their stakes in the business. Nicholas Investment Partners LP acquired a new stake in argenx SE during the second quarter worth approximately $236,000. DAFNA Capital Management LLC acquired a new stake in argenx SE during the second quarter worth approximately $848,000. Artal Group S.A. acquired a new stake in argenx SE during the third quarter worth approximately $1,229,000. Tekla Capital Management LLC acquired a new stake in argenx SE during the second quarter worth approximately $1,591,000. Finally, AWM Investment Company Inc. acquired a new stake in argenx SE during the second quarter worth approximately $2,121,000. 24.70% of the stock is currently owned by institutional investors.
About argenx SE
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The companys lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Receive News & Ratings for argenx SE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx SE and related companies with MarketBeat.com's FREE daily email newsletter.